- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
KCd Consolidation Does Not Show Noninferiority to ASCT in Transplant-Eligible, Newly Diagnosed Myeloma
June 8th 2021, 4:25pm
The 2-year progression free survival achieved with carfilzomib, cyclophosphamide, and dexamethasone consolidation did not prove to be noninferior to up-front autologous stem cell transplantation in newly diagnosed, transplant-eligible patients with multiple myeloma, although the margin is small.
Fracture Risk Reduced With BPAs During Radium-223/Enzalutamide Treatment in mCRPC
June 8th 2021, 3:45pm
Bone-protecting agents utilized during treatment with radium-223 plus enzalutamide reduced the risk for fractures in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer.
Regorafenib/Avelumab Combo Elicits Modest Activity in Heavily Pretreated Biliary Tract Cancer
June 8th 2021, 1:54pm
The addition of regorafenib to avelumab demonstrated modest anti-tumor responses and survival benefit in patients with heavily pretreated biliary tract cancer.
C-CAR039 Demonstrates Promising Efficacy, Safety in Relapsed/Refractory B-NHL
June 8th 2021, 1:40pm
The second-generation 4-1BB bi-specific CAR T-cell therapy C-CAR039 improved response rates and showed favorable safety in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Panitumumab Plus 5-FU/Leucovorin Maintenance Improves PFS in RAS Wild-Type Metastatic CRC
June 8th 2021, 12:18am
The addition of panitumumab to 5-fluorouracil and leucovorin significantly improved progression-free survival as a maintenance treatment over 5-FU/leucovorin alone in patients with RAS wild-type metastatic colorectal cancer.
Trastuzumab Deruxtecan Maintains Antitumor Activity in HER2+ mCRC
June 7th 2021, 11:57pm
Final results of the DESTINY-CRC01 trial were consistent with primary analysis, establishing the benefit of fam-trastuzumab deruxtecan-nxki in patients with HER2-overexpressing metastatic colorectal cancer.
Dr. Zalcberg on the Efficacy of Intra-Patient Dose Escalation With Ripretinib in Advanced GIST
June 7th 2021, 10:07pm
John Raymond Zalcberg, discusses the efficacy of intra-patient dose escalation with ripretinib in patients with advanced gastrointestinal stromal tumors, as demonstrated in an analysis of the phase 3 INVICTUS trial.
Dr. Tannir on Results With Telaglenastat/Cabozantinib in mRCC
June 7th 2021, 10:01pm
Nazir Tannir, MD, FACP, discusses the efficacy of the combination of telaglenastat and cabozantinib in patients with metastatic renal cell carcinoma, as demonstrated in the phase 2 CANTATA trial.
Tisagenlecleucel Induces High Rates of Durable Response in Relapsed/Refractory Follicular Lymphoma
June 7th 2021, 9:55pm
Tisagenlecleucel led to a high response rate that proved durable, along with a favorable safety profile, in patients with relapsed/refractory follicular lymphoma following treatment with at least 2 prior regimens, according to interim findings from the phase 2 ELARA trial.
Dr. Ailawadhi on the Efficacy of Lisaftoclax in Hematologic Malignancies
June 7th 2021, 9:30pm
Sikander Ailawadhi, MD, discusses the activity of lisaftoclax in patients with hematologic malignancies.
Dr. Short on the Activity of Ponatinib/Blinatumomab in Ph+ ALL
June 7th 2021, 9:30pm
Nicholas J. Short, MD, discusses the efficacy of the combination of ponatinib and blinatumomab in Philadelphia chromosome–positive acute lymphoblastic leukemia.
Pembrolizumab Plus Gemcitabine/Hypofractionated Radiotherapy Demonstrates Promising Efficacy in Muscle-Invasive Bladder Cancer
June 7th 2021, 9:22pm
Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiotherapy appears to be a promising and efficacious, bladder-sparing regimen for patients with muscle-invasive bladder cancer.
Dr. Abou-Alfa on Efficacy With Ivosidenib in IDH1+ Cholangiocarcinoma
June 7th 2021, 9:09pm
Ghassan K. Abou-Alfa, MD, discusses the efficacy of ivosidenib in IDH1-mutant cholangiocarcinoma based on the results of the phase 3 ClarIDHy study.
Dr. Litton on Responses to Talazoparib in BRCA1/2+ Early TNBC
June 7th 2021, 8:50pm
Jennifer Litton, MD, highlights responses to talazoparib seen in patients with BRCA1/2-positive, early triple-negative breast cancer.
First-Line Ibrutinib/Venetoclax Inhibits Response in CLL/SLL
June 7th 2021, 8:45pm
Ibrutinib plus venetoclax produced a complete response and complete response with incomplete bone marrow recovery rate of 56% in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
mFOLFOXIRI/Cetuximab Combo Improves Depth of Response in RAS Wild-Type mCRC
June 7th 2021, 8:40pm
Cetuximab added to mFOLFOXIRI induced superior depth of response than mFOLFOXIRI plus bevacizumab in treatment-naïve patients with RAS wild-type metastatic colorectal cancer.
Lisaftoclax Shows Early Safety, Efficacy in Relapsed/Refractory CLL/SLL and Other Hematologic Cancers
June 7th 2021, 8:32pm
The novel BCL-2 inhibitor lisaftoclax elicited encouraging responses with acceptable tolerability in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and other hematologic cancers.
Cetuximab Misses ORR End Point in RAS Wild-Type, BRAF V600E+ mCRC
June 7th 2021, 8:20pm
The chemotherapy regimen of FOLFOXIRI plus bevacizumab was found to be preferred in terms of antitumor activity compared with FOLFOXIRI plus cetuximab in patients with RAS wild-type, BRAF V600E–mutant metastatic colorectal cancer.
Pertuzumab/Trastuzumab Combo Elicits Clinical Activity in ERBB2/ERBB3+ Uterine Cancer
June 7th 2021, 8:12pm
The combination of pertuzumab and trastuzumab elicited a 37% disease control in patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer.
Updates in Genitourinary, Gynecologic Cancers From ASCO 2021: Drs Nick Vogelzang and Erin Crane
June 7th 2021, 8:00pm
OncLive News Network: On Location at ASCO 2021
OncLive sits down with Nicholas J. Vogelzang, MD, and Erin K. Crane, MD, MPH to discuss the biggest abstracts in genitourinary cancers and gynecologic cancers, respectively, at the 2021 ASCO Annual Meeting.